Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Incannex Healthcare reports quarterly loss per share of $0.15
Incannex Healthcare reported earnings per share of -$0.15 for the quarter ended June 30, 2026, presented at the finance conference on September 25, 2026. For the fiscal year it reported a loss per share of -$1.66, after -$40.50 in the prior year. » Mere på finanzen.net
Incannex Healthcare receives AUD 6.04m tax credit and expects a further AUD 5.1m
Incannex Healthcare has received a payment of AUD 6,039,162.43 from the Australian research and development incentive program and expects additional tax credits of AUD 5.1 million in 2026. The expected total proceeds from this non-dilutive capital therefore exceed AUD 11.1 million. The funds are intended to support further development of clinical programs such as IHL-42X and PSX-001 and capital allocation measures, including a share buyback program. » Mere på de.investing.com
Incannex starts DReAMzz study to optimise dosing of IHL-42X for obstructive sleep apnea
Incannex has begun the clinical DReAMzz crossover study to optimise dosing of IHL-42X (dronabinol/acetazolamide) for the treatment of obstructive sleep apnea. The company lists 14 identified study centres, completed manufacturing of the investigational products, and secured import/export approvals and distribution agreements to activate the sites. IHL-42X has Fast Track status with the FDA; Incannex notes rapid cash burn despite positive balance-sheet metrics and says adequate funding is critical (market capitalization: $53.8m; share price: $3.90). » Mere på de.investing.com
Incannex reactivates stock buyback program after pause
Incannex resumed its stock buyback program after a period of inactivity over the last two trading days and says it will opportunistically continue repurchasing shares. The biopharmaceutical company reports about $75 million in cash following a financing round, is debt-free and shows a very high short-term liquidity ratio (Current Ratio 48.27). The stock trades at $3.41, below the InvestingPro fair value of $4.06; as of 31.12.2025 roughly $18.5 million remained available for buybacks. Incannex stresses the decision reflects a discrepancy between market valuation and its financial position as well as progress in the clinical pipeline (including IHL-42X, PSX-001). » Mere på de.investing.com
Incannex has about $75m in cash after financing round and is debt-free
Incannex has roughly $75 million in cash following a financing round led by institutional healthcare investors and carries no debt. Market capitalization is around $46 million, which together with the liquidity position results in a negative enterprise value. The proceeds are intended primarily to fund the phase‑2 dosing‑optimization study DReAMzz for IHL‑42X (obstructive sleep apnea); IHL‑42X has FDA Fast Track status. The company plans dose administrations in the coming months, has an approved share buyback program, and is concurrently advancing development of PSX‑001 (oral synthetic psilocybin). » Mere på de.investing.com
Virksomhedstal
| (EUR) | 2023 | YoY |
|---|---|---|
| Omsætning | 618,83 t | 20,15 % |
| Bruttofortjeneste | 618,83 t | 21,13 % |
| Nettoresultat | -12,19 mio. | 122,65 % |
| EBITDA | -10,79 mio. | 361,24 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 8,73 mio. € |
Antal aktier | 347,71 mio. |
Højeste/laveste i 52 uger | 0,17 € - 0,0251 € |
| Udbytte | Nej |
Beta | 2,09 |
P/E (PE Ratio) | -2,88 |
PEG (PEG Ratio) | -0,03 |
K/I (PB Ratio) | 0,37 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
Incannex Healthcare Limited driver med forskning, udvikling og salg af medicinske cannabinoidprodukter i Australien. Selskabet tilbyder farmaceutisk kvalitets cannabinoidprodukter under varemærket Incannex. Selskabets produkter omfatter IHL-42X, som er i fase II kliniske forsøg for obstruktiv søvnapnø; IHL-216A til traumatisk hjerneskade; og IHL-675A, en kombination af hydroxychloroquin og cannabidiol til forebyggelse og behandling af inflammatoriske lungesygdomme, såsom akut respirationsbesvær-syndrom, kronisk obstruktiv lungesygdom, astma og bronkitis, samt reumatoid artritis og inflammatoriske tarmsygdomme. Selskabet har et partnerskab med The Alfred Hospital og Novotech om det kliniske program for IHL-42X vedrørende obstruktiv søvnapnø; og med Monash Trauma Group ved Department of Neuroscience, Monash University om at gennemføre et studie af den beskyttende effekt af IHL-216A ved sportsrelateret hjernerystelse. Selskabet var tidligere kendt som Impression Healthcare Limited og skiftede navn til Incannex Healthcare Limited i juni 2020. Incannex Healthcare Limited blev stiftet i 2001 og har hjemsted i Sydney, Australien.
| Navn | INCANNEX HEALTHCARE LTD. |
| CEO | Joel Bradley Latham |
| Hjemsted | Sydney,
nsw Australien |
| Websted | |
| Børsnotering | 23.05.2007 |
| Medarbejdere | 3 |
Tickersymboler
| Børs | Symbol |
|---|---|
Australian Securities Exchange Ltd | IHL.AX |